Details of Disease

General Information of Disease (ID: DISRQXWI)

• Disease Name: Constipation
• Synonyms: colonic inertia; Dyschezia; constipation
• Disease Class: DD91: Irritable bowel syndrome
• Definition: Irregular and infrequent or difficult evacuation of the bowels.
• Disease Hierarchy:
  DISWD40R: Disease
  DISL9FWR: Bowel dysfunction
  DISRQXWI: Constipation
• ICD Code:
  ICD-11: ICD-11: DD91.1
  ICD-10: ICD-10: K59.0
  ICD-9: ICD-9: 564
  Expand ICD-11: 'DB32.1; 'DD91.1
  Expand ICD-10: 'K59.0
  Expand ICD-9: 564
• Disease Identifiers:
  MONDO ID: MONDO_0002203
  MESH ID: D003248
  UMLS CUI: C0009806
  MedGen ID: 1101
  HPO ID: HP:0002019
  SNOMED CT ID: 14760008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bisacodyl	DM178H9	Approved	Small molecular drug	[1]
Castor oil	DMMS8JB	Approved	Small molecular drug	[1]
Dehydrocholic acid	DMFK8Y9	Approved	Small molecular drug	[1]
Docusate	DMYG4Y2	Approved	Small molecular drug	[1]
HTF 919	DM78G6F	Approved	Small molecular drug	[1]
Lactulose	DMSAOWQ	Approved	Small molecular drug	[1]
MD-1100	DM4IAKR	Approved	Small molecular drug	[2]
Mineral oil	DM3GYS3	Approved	NA	[1]
Phosphate	DMUXQG7	Approved	Small molecular drug	[1]
Polyethylene glycol	DM4I1JP	Approved	Small molecular drug	[1]
R0-93877	DMM4U9G	Approved	Small molecular drug	[1]
Sodium lauryl sulfate	DMLJ634	Approved	Small molecular drug	[3]
Sorbitol	DMAN0DE	Approved	Small molecular drug	[1]
Tenapanor	DMCOZJY	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALKS-37	DM5OY3N	Phase 2	NA	[5]
DSP-6952	DM6UGHA	Phase 2	NA	[6]
YKP-GI	DM740LV	Phase 2	Small molecular drug	[7]
STD-07	DMMWTN6	Phase 1/2	NA	[8]
DS-3801	DM6WN9X	Phase 1	NA	[9]

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Phenolphthalein	DM5SICT	Withdrawn from market	Small molecular drug	[1]
ADL-5945	DMQM54P	Discontinued in Phase 2	NA	[10]
NT-3	DMGZ3DR	Discontinued in Phase 2	NA	[11]
ADL-7445	DML1AUZ	Discontinued in Phase 1	NA	[12]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CB-01-16	DMKFAG3	Preclinical	NA	[13]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KRP-110	DME9HZC	Investigative	NA	[14]
MDT-006	DMSF4UI	Investigative	NA	[15]
SPIRU-211	DMAISVV	Investigative	NA	[16]
STD-052	DMS7VFU	Investigative	NA	[16]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 42 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
COMT	TTKWFB8	Limited	Biomarker	[17]
DDC	TTN451K	Limited	Genetic Variation	[18]
KIT	TTX41N9	Limited	Biomarker	[19]
LRRK2	TTK0FEA	Limited	Biomarker	[20]
MAP2K1	TTIDAPM	Limited	CausalMutation	[21]
MECP2	TTTAU9R	Limited	Genetic Variation	[22]
PON1	TT9LX82	Limited	Biomarker	[23]
SLC6A3	TTVBI8W	Limited	Biomarker	[24]
SNCA	TT08OSU	Limited	Biomarker	[25]
TTR	TTPOYU7	Limited	Altered Expression	[26]
FLNA	TTSTRZY	moderate	Genetic Variation	[27]
OPRM1	TTKWM86	moderate	Biomarker	[28]
PYY	TTVFJLX	moderate	Genetic Variation	[29]
ADRA2C	TT2NUT5	Strong	Genetic Variation	[30]
AQP3	TTLDNMQ	Strong	Altered Expression	[31]
AQP9	TTQEI32	Strong	Altered Expression	[31]
ATP4A	TTF1QVM	Strong	Genetic Variation	[32]
CD160	TTOFEAS	Strong	Altered Expression	[33]
CHAT	TTKYFSB	Strong	Altered Expression	[34]
CHRM3	TTQ13Z5	Strong	Genetic Variation	[17]
CLCN2	TT30NW6	Strong	Biomarker	[35]
EDNRB	TT3ZTGU	Strong	Biomarker	[36]
FFAR2	TT0FYAN	Strong	Altered Expression	[34]
FGF19	TTGCH11	Strong	Biomarker	[37]
GAST	TT4LRVO	Strong	Biomarker	[38]
GCG	TT6Y4PN	Strong	Biomarker	[39]
GDNF	TTF23ML	Strong	Altered Expression	[40]
GP1BA	TTVB0Q9	Strong	Biomarker	[41]
GPBAR1	TTSDVTR	Strong	Biomarker	[42]
GUCY2C	TTLDPRG	Strong	Genetic Variation	[43]
HTR4	TT07C3Y	Strong	Biomarker	[44]
HTR7	TTO9X1H	Strong	Genetic Variation	[17]
MGAM	TTXWASR	Strong	Genetic Variation	[45]
MYLK2	TTHLGB2	Strong	Altered Expression	[46]
NPR3	TTWVLS6	Strong	Biomarker	[47]
OPRD1	TT27RFC	Strong	Biomarker	[48]
POMC	TT21AKM	Strong	Biomarker	[49]
RET	TT4DXQT	Strong	Genetic Variation	[50]
STC1	TTDLUER	Strong	Genetic Variation	[51]
THRA	TTTSEPU	Strong	Biomarker	[52]
TPH1	TTZSJHV	Strong	Biomarker	[18]
VIP	TTGTWLF	Strong	Altered Expression	[31]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	Strong	Genetic Variation	[32]
SLC26A3	DTN1FMD	Strong	Biomarker	[53]
SLC35A2	DT0567K	Strong	Genetic Variation	[54]

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
FAAH	DEUM1EX	Limited	Altered Expression	[55]
MANBA	DEMH6UB	Strong	Biomarker	[56]
SI	DE5EO4Y	Strong	Genetic Variation	[45]
UGT1A9	DE85D2P	Strong	Biomarker	[57]

This Disease Is Related to 30 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PACS1	OT9TMQL3	Limited	Genetic Variation	[58]
PHOX2B	OT3SFR2O	Limited	Genetic Variation	[59]
MED13	OTP5LEJE	moderate	Biomarker	[60]
ARMC9	OT0MZER2	Strong	Biomarker	[61]
BPTF	OTD1RZAD	Strong	CausalMutation	[62]
CAMK2B	OTS9YK3E	Strong	CausalMutation	[63]
CHD4	OTBDEHDP	Strong	Genetic Variation	[64]
CHSY3	OT8ERGMH	Strong	Biomarker	[65]
COG2	OTKQH4N4	Strong	Biomarker	[66]
CREB3L1	OT2JHIHM	Strong	Biomarker	[67]
DEAF1	OTCLX3ZW	Strong	Genetic Variation	[68]
IGSF1	OT3XD6U2	Strong	Genetic Variation	[69]
LGALS14	OTOR23GX	Strong	Biomarker	[35]
MITF	OT6XJCZH	Strong	CausalMutation	[70]
MLN	OTBZ5SE5	Strong	Altered Expression	[31]
MTFMT	OT1OIVJL	Strong	Biomarker	[71]
MYLK3	OTC58V2Q	Strong	Altered Expression	[46]
NCOA6	OTOMIGTV	Strong	Biomarker	[72]
NEUROG3	OT6DIPWC	Strong	Biomarker	[73]
NID1	OTKLBLS6	Strong	Genetic Variation	[74]
NPS	OTEG25A2	Strong	Biomarker	[75]
NTS	OTPGDNQS	Strong	Genetic Variation	[76]
NXPH1	OTGKX860	Strong	Genetic Variation	[77]
OR2AG1	OTEITRP4	Strong	Genetic Variation	[78]
PACC1	OTKBS8CC	Strong	Biomarker	[79]
SOX4	OTSS40SS	Strong	Genetic Variation	[80]
SYNM	OTOI8TRJ	Strong	Biomarker	[81]
TAC1	OTM842YW	Strong	Altered Expression	[31]
TNXB	OTVBWAV5	Strong	Biomarker	[82]
TP53INP2	OT0GTBXO	Strong	Biomarker	[48]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [3] Drug information of Sodium lauryl sulfate, 2008. eduDrugs.
• [4] ClinicalTrials.gov (NCT01340053) A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01382797) ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC). U.S. National Institutes of Health.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034751)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8427).
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024780)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040749)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030930)
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5033).
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031260)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030751)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).
• [16] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [17] Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine.J Clin Psychopharmacol. 2018 Jun;38(3):193-199. doi: 10.1097/JCP.0000000000000885.
• [18] Serotonin and tryptophan metabolites, autoantibodies and gut microbiome in APECED.Endocr Connect. 2019 Jan 1;8(1):69-77. doi: 10.1530/EC-18-0513.
• [19] Expression of c-kit messenger ribonucleic acid and c-kit protein in sigmoid colon of patients with slow transit constipation.Int J Colorectal Dis. 2005 Jul;20(4):363-7. doi: 10.1007/s00384-004-0679-0. Epub 2005 Feb 2.
• [20] Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.Neurobiol Aging. 2014 Mar;35(3):725.e1-6. doi: 10.1016/j.neurobiolaging.2013.08.012. Epub 2013 Oct 3.
• [21] Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.Eur J Hum Genet. 2009 Jun;17(6):733-40. doi: 10.1038/ejhg.2008.256. Epub 2009 Jan 21.
• [22] Altered gut microbiota in Rett syndrome.Microbiome. 2016 Jul 30;4(1):41. doi: 10.1186/s40168-016-0185-y.
• [23] Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.Toxicol Lett. 2009 Apr 10;186(1):66-72. doi: 10.1016/j.toxlet.2008.10.018. Epub 2008 Oct 28.
• [24] Constipation is not associated with dopamine transporter pathology in early drug-nave patients with Parkinson's disease.Eur J Neurol. 2018 Feb;25(2):307-312. doi: 10.1111/ene.13503. Epub 2017 Dec 11.
• [25] Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review.J Neurogastroenterol Motil. 2018 Jan 30;24(1):30-42. doi: 10.5056/jnm17105.
• [26] Investigation on the frailty status of the elderly inpatients in Shanghai using the FRAIL (fatigue, resistance, ambulation, illness, and loss) questionnaire.Medicine (Baltimore). 2018 May;97(18):e0581. doi: 10.1097/MD.0000000000010581.
• [27] Filamin A mutation is one cause of FG syndrome. Am J Med Genet A. 2007 Aug 15;143A(16):1876-9. doi: 10.1002/ajmg.a.31751.
• [28] Combining opioids and non-opioids for pain management: Current status.Neuropharmacology. 2019 Nov 1;158:107619. doi: 10.1016/j.neuropharm.2019.04.025. Epub 2019 Apr 25.
• [29] An Ovarian Carcinoid Tumor With Peptide YY-Positive Insular Component: A Case Report and Review of the Literature.Int J Gynecol Pathol. 2016 Jul;35(4):362-8. doi: 10.1097/PGP.0000000000000242.
• [30] Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders.Gut. 2004 Jun;53(6):829-37. doi: 10.1136/gut.2003.030882.
• [31] Protective effect of mulberry (Morus atropurpurea) fruit against diphenoxylate-induced constipation in mice through the modulation of gut microbiota.Food Funct. 2019 Mar 20;10(3):1513-1528. doi: 10.1039/c9fo00132h.
• [32] Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants.Therap Adv Gastroenterol. 2019 Jul 12;12:1756284819853790. doi: 10.1177/1756284819853790. eCollection 2019.
• [33] Cyclooxygenase-dependent alterations in substance P-mediated contractility and tachykinin NK1 receptor expression in the colonic circular muscle of patients with slow transit constipation.J Pharmacol Exp Ther. 2009 Apr;329(1):282-9. doi: 10.1124/jpet.108.148148. Epub 2009 Jan 22.
• [34] Function and clinical implications of short-chain fatty acids in patients with mixed refractory constipation.Colorectal Dis. 2016 Aug;18(8):803-10. doi: 10.1111/codi.13314.
• [35] Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.Dig Dis Sci. 2011 Feb;56(2):339-51. doi: 10.1007/s10620-010-1495-8. Epub 2010 Dec 8.
• [36] Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus.J Med Genet. 1994 Aug;31(8):602-6. doi: 10.1136/jmg.31.8.602.
• [37] Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.Aliment Pharmacol Ther. 2019 Mar;49(6):744-758. doi: 10.1111/apt.15106. Epub 2019 Feb 10.
• [38] Laxative Effects of Taurine on Loperamide-Induced Constipation in Rats.Adv Exp Med Biol. 2019;1155:261-271. doi: 10.1007/978-981-13-8023-5_25.
• [39] The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome.Neurogastroenterol Motil. 2020 Feb;32(2):e13738. doi: 10.1111/nmo.13738. Epub 2019 Oct 11.
• [40] Lactobacillus plantarum CQPC02-Fermented Soybean Milk Improves Loperamide-Induced Constipation in Mice.J Med Food. 2019 Dec;22(12):1208-1221. doi: 10.1089/jmf.2019.4467. Epub 2019 Oct 17.
• [41] Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients.J Ren Nutr. 2020 Jan;30(1):31-35. doi: 10.1053/j.jrn.2019.02.004. Epub 2019 Apr 5.
• [42] The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice.Gastroenterology. 2013 Jan;144(1):145-54. doi: 10.1053/j.gastro.2012.09.055. Epub 2012 Oct 3.
• [43] Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress.Neurogastroenterol Motil. 2018 Oct;30(10):e13375. doi: 10.1111/nmo.13375. Epub 2018 May 24.
• [44] Should We Use Tegaserod for Irritable Bowel Syndrome?.Am J Ther. 2019 May/Jun;26(3):e417-e420. doi: 10.1097/MJT.0000000000000947.
• [45] Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.J Diabetes Investig. 2018 Jan;9(1):127-136. doi: 10.1111/jdi.12686. Epub 2017 Jun 12.
• [46] Ardipusilloside-I stimulates gastrointestinal motility and phosphorylation of smooth muscle myosin by myosin light chain kinase.Korean J Physiol Pharmacol. 2017 Nov;21(6):609-616. doi: 10.4196/kjpp.2017.21.6.609. Epub 2017 Oct 30.
• [47] Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation.PLoS One. 2017 Sep 28;12(9):e0185496. doi: 10.1371/journal.pone.0185496. eCollection 2017.
• [48] Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes.Life Sci. 2018 Dec 15;215:246-252. doi: 10.1016/j.lfs.2018.07.028. Epub 2018 Jul 21.
• [49] Efficacy and tolerability of olive oil-based ketogenic diet in children with drug-resistant epilepsy: A single center experience from Turkey.Eur J Paediatr Neurol. 2019 Jan;23(1):143-151. doi: 10.1016/j.ejpn.2018.11.007. Epub 2018 Nov 20.
• [50] Constipation with megacolon in a 36-year-old man: a rare presentation of MEN2B from Sri Lanka.BMJ Case Rep. 2019 Jan 14;12(1):bcr-2018-227081. doi: 10.1136/bcr-2018-227081.
• [51] Colonic Transit Time and Gut Peptides in Adult Patients with Slow and Normal Colonic Transit Constipation.Biomed Res Int. 2017;2017:3178263. doi: 10.1155/2017/3178263. Epub 2017 Sep 7.
• [52] Diverse Genotypes and Phenotypes of Three Novel Thyroid Hormone Receptor- Mutations.J Clin Endocrinol Metab. 2016 Aug;101(8):2945-54. doi: 10.1210/jc.2016-1404. Epub 2016 May 4.
• [53] 4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation.J Med Chem. 2019 Sep 12;62(17):8330-8337. doi: 10.1021/acs.jmedchem.9b01192. Epub 2019 Sep 3.
• [54] SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.Hum Mutat. 2019 Jul;40(7):908-925. doi: 10.1002/humu.23731. Epub 2019 Apr 24.
• [55] Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans.Neurogastroenterol Motil. 2018 Sep;30(9):e13370. doi: 10.1111/nmo.13370. Epub 2018 May 10.
• [56] Study on the ability of partially hydrolyzed guar gum to modulate the gut microbiota and relieve constipation.J Food Biochem. 2019 Feb;43(2):e12715. doi: 10.1111/jfbc.12715. Epub 2018 Nov 14.
• [57] Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.Transpl Immunol. 2013 Dec;29(1-4):155-61. doi: 10.1016/j.trim.2013.05.005. Epub 2013 May 27.
• [58] Schuurs-Hoeijmakers syndrome in two patients from Japan.Am J Med Genet A. 2019 Mar;179(3):341-343. doi: 10.1002/ajmg.a.9. Epub 2018 Dec 27.
• [59] An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management.Am J Respir Crit Care Med. 2010 Mar 15;181(6):626-44. doi: 10.1164/rccm.200807-1069ST.
• [60] De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder. Hum Genet. 2018 May;137(5):375-388. doi: 10.1007/s00439-018-1887-y. Epub 2018 May 8.
• [61] Examining Balloon Expulsion Testing as an Office-Based, Screening Test for Dyssynergic Defecation: A Systematic Review and Meta-Analysis.Am J Gastroenterol. 2018 Nov;113(11):1613-1620. doi: 10.1038/s41395-018-0230-5. Epub 2018 Aug 31.
• [62] Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features. Am J Hum Genet. 2017 Oct 5;101(4):503-515. doi: 10.1016/j.ajhg.2017.08.014. Epub 2017 Sep 21.
• [63] De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability. Am J Hum Genet. 2017 Nov 2;101(5):768-788. doi: 10.1016/j.ajhg.2017.10.003.
• [64] Treatment and Patient Reported Outcome in Children with Hirschsprung Disease and Concomitant Congenital Heart Disease.Biomed Res Int. 2017;2017:1703483. doi: 10.1155/2017/1703483. Epub 2017 Mar 8.
• [65] Long-term comparison of physiologic anorectal changes and recurrence between transanal repair and transanal repair with posterior colporrhaphy in rectocele.Asian J Surg. 2020 Jan;43(1):265-271. doi: 10.1016/j.asjsur.2019.04.001. Epub 2019 Apr 26.
• [66] A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes.Nutr Metab (Lond). 2018 May 9;15:36. doi: 10.1186/s12986-018-0273-z. eCollection 2018.
• [67] Acupuncture for constipation in patients with stroke: protocol of a systematic review and meta-analysis.BMJ Open. 2018 Mar 30;8(3):e020400. doi: 10.1136/bmjopen-2017-020400.
• [68] Functional analysis of novel DEAF1 variants identified through clinical exome sequencing expands DEAF1-associated neurodevelopmental disorder (DAND) phenotype.Hum Mutat. 2017 Dec;38(12):1774-1785. doi: 10.1002/humu.23339. Epub 2017 Sep 23.
• [69] A Japanese patient with congenital central hypothyroidism caused by a novel IGSF1 mutation.J Pediatr Endocrinol Metab. 2018 Mar 28;31(3):355-359. doi: 10.1515/jpem-2017-0144.
• [70] Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.JAMA Dermatol. 2016 Apr;152(4):405-12. doi: 10.1001/jamadermatol.2015.4356.
• [71] Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria.Haematologica. 2019 Aug;104(8):1682-1688. doi: 10.3324/haematol.2018.198549. Epub 2019 Feb 7.
• [72] Different perception of chronic constipation between patients and gastroenterologists.Neurogastroenterol Motil. 2018 Mar 25:e13336. doi: 10.1111/nmo.13336. Online ahead of print.
• [73] Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome.BMC Gastroenterol. 2017 Aug 1;17(1):90. doi: 10.1186/s12876-017-0643-4.
• [74] Neuronal intestinal dysplasia: clinical experience in Italian patients.Eur J Pediatr Surg. 1994 Oct;4(5):287-92. doi: 10.1055/s-2008-1066119.
• [75] Clinical Outcomes in Early Cervical Cancer Patients Treated with Nerve Plane-sparing Laparoscopic Radical Hysterectomy.J Minim Invasive Gynecol. 2020 Mar-Apr;27(3):687-696. doi: 10.1016/j.jmig.2019.04.025. Epub 2019 May 7.
• [76] The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio.Eur J Pharmacol. 2019 Apr 5;848:80-87. doi: 10.1016/j.ejphar.2019.01.048. Epub 2019 Jan 29.
• [77] Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome.Gut. 2014 Jul;63(7):1103-11. doi: 10.1136/gutjnl-2013-304570. Epub 2013 Sep 16.
• [78] Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.PLoS One. 2017 Mar 14;12(3):e0172846. doi: 10.1371/journal.pone.0172846. eCollection 2017.
• [79] Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.J Clin Gastroenterol. 2020 Apr;54(4):365-369. doi: 10.1097/MCG.0000000000001239.
• [80] De Novo SOX4 Variants Cause a Neurodevelopmental Disease Associated with Mild Dysmorphism. Am J Hum Genet. 2019 Feb 7;104(2):246-259. doi: 10.1016/j.ajhg.2018.12.014. Epub 2019 Jan 17.
• [81] Gut Microbiota-Based Therapies for Irritable Bowel Syndrome.Clin Transl Gastroenterol. 2018 Feb 15;9(2):e134. doi: 10.1038/ctg.2018.2.
• [82] The extracellular matrix glycoprotein tenascin-X regulates peripheral sensory and motor neurones.J Physiol. 2018 Sep;596(17):4237-4251. doi: 10.1113/JP276300. Epub 2018 Jul 18.